astrazeneca plc ˌæstrəˈzɛnəkə angloswedish multinational pharmaceutical biotechnology headquarters cambridge biomedical campus cambridge portfolio products major diseases areas including oncology cardiovascular gastrointestinal infection neuroscience respiratory inflammation involved developing company founded merger swedish astra ab british zeneca formed demerger pharmaceutical operations imperial chemical industries since merger among worlds largest pharmaceutical companies made numerous corporate acquisitions including cambridge antibody technology medimmune spirogen definiens medimmune research development concentrated three strategic centres cambridge england gothenburg sweden gaithersburg maryland astrazeneca traces earliest corporate history astra ab formed large group doctors apothecaries södertälje throughout twentieth century grew largest pharmaceutical company sweden british counterpart zeneca plc formed ici divested pharmaceuticals businesses astra ab zeneca plc merged six years later chosen headquarters united astrazenecas primary listing london stock exchange constituent ftse index also secondary listing nasdaq stockholm astrazeneca one highest market capitalisations pharmaceutical companies astra ab founded södertälje sweden doctors british chemicals company ici established four british chemical companies demerged pharmaceuticals businesses agrochemicals specialities businesses form zeneca group finally astra zeneca group merged form astrazeneca plc headquarters astrazeneca identified new location companys us base fairfaxplus site north wilmington drug iressa gefitinib approved japan monotherapy nonsmall cell lung january dr robert nolan former director astrazeneca formed management team zi company acquired kudos pharmaceuticals uk biotech company entered anticancer collaboration agreement also announced become diamond member pennsylvania bio commerce following collaborative relationship begun astrazeneca acquired cambridge antibody technology february astrazeneca agreed buy arrow therapeutics company focused discovery development antiviral therapies astrazenecas pipeline patent cliff subject much speculation april leading pipelineboosting collaboration acquisition days later astrazeneca acquired us company medimmune billion gain flu vaccines antiviral treatment astrazeneca subsequently consolidated biologics operations dedicated biologics division called astrazeneca acquired novexel corp antibiotics discovery company formed spinoff sanofiaventis antiinfectives division astra acquired experimental antibiotic cazavi astrazeneca acquired guangdong beikang pharmaceutical company chinese generics february astrazeneca amgen announced collaboration treatments inflammatory april astrazeneca acquired ardea biosciences another biotechnology company june astrazeneca bristol myers squibb announced twostage deal joint acquisition biotechnology company amylin agreed bristol myers squibb would acquire amylin billion cash assumption billion debt astrazeneca paying billion cash bristol myers squibb amylin folded existing diabetes joint venture astrazeneca bristol myers march astrazeneca announced plans major corporate restructuring including closure research development activities alderley park cheshire loughborough uk lund sweden investment million construction new research development facility cambridge concentration rd three locations cambridge gaithersburg maryland location medimmune work biotech drugs gothenburg sweden research traditional chemical astrazeneca also announced would move corporate headquarters london cambridge announcement included announcement would cut jobs three days later announced would cut additional also announced would focus three therapeutic areas respiratory inflammation autoimmunity cardiovascular metabolic disease october astrazeneca announced would acquire biotech oncology company spirogen around may astrazeneca rejected final offer pfizer per share valued company billion billion companies meeting since january takeover proceeded pfizer would become worlds biggest drug maker transaction would also biggest foreign takeover british company many britain including politicians scientists opposed july company entered deal almirall acquire subsidiary almirall sofotec lung treatments including copd drug eklira billion deal included allocation billion development respiratory franchise one astrazenecas three target therapeutic areas announced year august company announced entered threeyear collaboration mitsubishi tanabe pharma diabetic september company would join forces eli lilly developing commercialising candidate bace inhibitor used treatment alzheimers disease deal could yield million november companys biologics rd operation medimmune agreed acquire definiens million company also began phase iii trial collaboration pharmacyclics janssen biotech investigating combination also november year company agreed sell lipodystrophy treatment business aegerion pharmaceuticals december company received accelerated fda approval olaparib treatment women advanced ovarian cancer brca genetic mutation major criterion governing drugs approval average ability shrink tumours patients february company announced would acquire us canadian rights actaviss branded respiratory drug business initial sum later month company announced would partner orca pharmaceuticals develop retinoic acidrelated orphan nuclear receptor gamma inhibitors use treatment number autoimmune diseases could generate million company also announced plan spend million creating new subsidiary focused small molecule antiinfectives primarily research gyrase inhibitor currently phase ii treatment company underwrote twenty thirtytwo seats new gothenburg service sunair midmarch company announced would cocommercialise naloxegol along daiichi sankyo deal worth towards end april company announced number collaborations worth estimated billion first develop commercialise celgene use nonhodgkin lymphoma myelodysplastic syndromes multiple myeloma astrazeneca receiving million second two deals agreement study combination treatment innate pharmas phase ii antibody billion companys medimmune arm also launched collaborative clinical trials juno therapeutics investigating combination treatments trials assess combinations one juno therapeutics directed chimeric antigen receptor tcell late june company announced entered partnership agreement eolas therapeutics eolas receptor antagonist eora program smoking cessation july company announced would sell rights entocort budesonide tillotts pharma july genzyme announced would acquire rare cancer drug caprelsa vandetanib astrazeneca august company announced acquired global rights develop commercialise heptares therapeutics drug candidate focuses blocking adenosine receptor deal worth month companys medimmune subsidiary acquired exclusive rights inovio pharmaceuticals immunotherapy currently phase iii agreement could net million inovio targets human papillomavirus types september valeant licensed brodalumab company november reported astrazeneca acquired zs pharma december company announced intention acquire respiratory portfolio takeda pharmaceutical namely alvesco omnaris day later company announced taken majority stake acerta billion part transaction company gain commercial rights acertas irreversible oral brutons tyrosine kinase inhibitor acalabrutinib currently phase iii development bcell blood cancers phase ii clinical trials solid eighthlargest drug company world based sales july companys ceo pascal soriot said brexit would affect commitment current plans united kingdom however slowed decision making new investment projects waiting postbrexit regulatory regime settle september companys chairman leif johansson planned taking first steps moving research manufacturing operations away united kingdom hard eleventh largest drug company world based sales ranked seventh based rd january evp pam cheng stated astrazeneca ignited startup duplicate qa testing facility sweden initiated hiring february astrazeneca announced spinning six earlystage experimental drugs new biotechnology company known viela bio valued december astrazeneca purchased nearly american pharmaceutical business march astrazeneca announced pay billion work daiichi sankyo co ltd experimental treatment breast cancer astrazeneca plans use proceeds billion share issue fund deal deal drug known trastuzumab deruxtecan sent shares japans daiichi soaring september company announced would cease drug production german headquarters wedel leading loss jobs end october astrazeneca announced would sell global commercial rights drug treat acid reflux german pharmaceutical company cheplapharm arzneimittel gmbh much february astrazeneca agreed sublicense global rights except europe canada israel drug movantik redhill june astrazeneca made preliminary approach gilead sciences potential merger worth almost however plans subsequently dropped would distracted company pipeline ongoing vaccine july business entered second collaboration daiichi sankyo centred around development antibody drug conjugate deal could potentially worth billion september astrazeneca acquired preclinical oral inhibitor program dogma december astrazeneca ceo pascal soriot said figured winning formula twodose system oxford university december united kingdom approved emergency use july astrazeneca acquired alexion october company alexion acquired caelum biosciences monoclonal treatment light chain al amyloidosis july company announced would acquire teneotwo billion increasing blood cancer drug october announced company would acquire logicbio therapeutics active clinicalstage genomic november announced astrazeneca acquired amsterdamheadquartered clinicalstage biotechnology company neogene january astrazeneca announced would acquire cincor pharma november astrazeneca launched new global health tech business evinova focused provide global services cros pharma companies design run monitor clinical march company announced would donating ppe including million face masks help support various international health organisations mitigating april chief executive pascal soriot reported company working glaxosmithkline university cambridge develop new laboratory capable conducting tests per company also announced plans clinical trial assess potential use calquence treatment june national institute allergy infectious diseases niaid confirmed third phase testing potential vaccines developed oxford university astrazeneca would begin july one reached phase iii november announced vaccines successful trial preventing people developing researchers thought figure might high tweaked january india approved use vaccine paving way mass immunisation campaign worlds second populous country announced shot would made locally serum institute india sii brand name january european medicines agency ema recommended granting conditional marketing authorisation people years midmarch netherlands denmark norway iceland bulgaria ireland suspended use astrazeneca vaccine due worries six cases rare combination blood clots lowered blood platelets see embolic thrombotic events vaccination temporary halt advice european unions medicines regulator said benefits vaccine still outweigh potential ema issued statement march stating association vaccination astrazeneca vaccines clotrelated cases found could ruled investigations carried ema also stressed benefits astrazeneca vaccine outweigh risks possible side march swedish medicines agency läkemedelsverket announced following prior approval would change name vaccine vaxzevria stressing name vaccine would change april ema head vaccines marco cavaleri announced could declared link vaxzevria vaccine rare blood clots associated low platelet statement following day ema confirmed link continued recommend vaccine saying benefits vaccine far outweigh later scottish vaccine efficacy study confirmed validity statement showing percent reduction risk hospitalization first dose vaxzevria fourth week european medicines agency also identified time development rare neurological disease guillainbarré syndrome gbs possible side effect vaxzevria time emas decision september guillainbarré syndrome unlikely occurred cases gbs reported months following administration million doses december scientists arizona state university cardiff university identified trigger behind blood clots professor alan parker said data confirms bind adenoviruses important step unravelling mechanism underlying vitta establishing mechanism could help prevent treat disorder april european commission announced would sue astra zeneca delaying timely delivery vaxzevria time every vaccine counts every vaccine save september lawsuit finally settled astrazeneca agreeing deliver million doses vaccines eu member states october million end year million april following illustration companys major mergers acquisitions historical astrazeneca develops manufactures sells pharmaceutical biotechnology products treat disorders oncology cardiovascular gastrointestinal infection neuroscience respiratory inflammation astrazeneca corporate headquarters cambridge united kingdom main research development rd centres cambridge uk gaithersburg maryland us gothenburg sweden warsaw april astrazenecas drug tremelimumab approved orphan drug treatment mesothelioma united february astrazeneca announced clinical trial tremelimumab treatment mesothelioma failed meet primary david brennan paid role chief executive april announced brennan retire early june august pascal soriot named ceo also announced leif johansson would succeed louis schweitzer nonexecutive chairman june three months earlier previously announced would become chairman nomination governance committee annual general companys nonexecutive board directors philip broadley euan ashley michel demaré deborah disanzo diana layfield sheri mccoy tony mok nazneen rahman andreas rummelt marcus astrazeneca member personalized medicine coalition medical research advocacy group lobbies behalf pharmaceutical astrazenecas reputation china tarnished following failure chinese subsidiary timely donate relief efforts following sichuan typically donations disaster relief china made funds established chinese ministry civil affairs subordinate organization red cross society astrazeneca corporate rule prohibiting foreign subsidiaries making donations local governments company construed rule prohibiting donations sichuan earthquake relief astrazenecas chinese subsidiary received major backlash failure corporate approval ultimately given chinese subsidiary donate approval came long april astrazeneca settled qui tam lawsuit brought stefan p kruszewski million settle allegations company defrauded medicare medicaid governmentfunded health care programs connection marketing promotional practices blockbuster atypical antipsychotic seroquel according settlement agreement astrazeneca targeted illegal marketing antipsychotic seroquel towards doctors typically treat schizophrenia bipolar disorder physicians treat elderly primary care physicians pediatric adolescent physicians longterm care facilities march astrazeneca settled lawsuit united states totalling million divided companys commercially successful medication esomeprazole nexium primary uses treatment gastroesophageal reflux disease treatment maintenance erosive esophagitis treatment duodenal ulcers caused helicobacter pylori prevention gastric ulcers chronic nsaid therapy treatment gastrointestinal ulcers associated crohns disease manufactured result mixture two mirrorimaged molecules r two years omeprazole patent expired astrazeneca patented someprazole pure form pointing since people metabolise romeprazole slowly pure someprazole treatment would give higher dose efficiency less variation march company began market nexium would brand new renantiomer omeprazole metabolized exclusively enzyme expressed low amounts population treated normal dose enantiomeric mixture persons experience blood levels fivetimes higher normal production contrast esomeprazole metabolized providing lessvariable drug omeprazole approved doses mg treatment gastroesophageal esomeprazole approved doses marcia angell former editorinchief new england journal medicine lecturer social medicine harvard medical school said stern germanlanguage weekly newsmagazine astrazenecas scientists misrepresented research drugs efficiency saying instead using presumably comparable doses drug companys scientists used nexium higher dosages compared mg nexium mg prilosec cards marked way nexium looked like improvement however small shown two three february astra usa sued lars bildman former president chief executive officer seeking million defrauding sum included million company funds allegedly used fix three homes plus money company paid result eeoc investigation astras lawsuit alleged bildman sexually harassed intimidated employees used company funds yachts prostitutes destroyed documents records concocted tales conspiracy involving exkgb agents competitors lastditch effort distract attention real wrongdoer bildman bildman already pleaded guilty us district court failing report million income tax addition several female coworkers filed personal sexualharassment lawsuits april bildman sentenced months prison three months pled guilty filing false federal tax february astrazenacas us affiliate astra usa agreed million settlement equal employment opportunity commission investigation started may found sexual harassment female former female employees astra interviewed inquiry identified able file astra usa also issued statement apology hostile work astra usa v bildman mass applying new yorks faithless servant doctrine court held companys employee engaged financial misdeeds sexual harassment must forfeit salary bonuses period court held case even employee otherwise performed valuable services employee entitled recover restitution value decision attracted good deal attention legal university minnesota research participant dan markingson committed suicide enrolled industrysponsored pharmaceutical trial comparing three fdaapproved atypical antipsychotics seroquel quetiapine zyprexa olanzapine risperdal risperidone university minnesota professor bioethics carl elliott noted markingson enrolled study wishes mother mary weiss forced choose enrolling study involuntarily committed state mental fda investigation cleared university nonetheless controversy around case continued mother jones resulted group university faculty members sending public letter university board regents urging external investigation markingsons astrazeneca agreed pay million settle uk tax dispute related transfer august astrazeneca declared towards european commission eu member states however uk secretary state health social care matt hancock declared march united kingdom given exclusivity eus treaty placing order astrazenecas vaccine european commission mistakenly assumed enough vaccines initially ordered million doses manufacturers offered million doses eu november however contract astrazeneca reached uk similar reached eu also contained phrase best reasonable efforts uk contract signed august day contract key difference seems astrazeneca entered preliminary agreement uk back may arranged development dedicated supply chain failure produce vaccine anticipated quantities contributed low vaccination rates vulnerable populations european union beginning outbreak virulent variants early may astrazenecas china president said company aims patriotic company china loves communist httpsenwikipediaorgwikiastrazeneca